Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Diminishing Cash, Aryx Seeks Pharma Partners For Mid-Stage Assets

This article was originally published in The Pink Sheet Daily

Executive Summary

Management expects clarity from FDA on the clinical development program for two drugs that will help finalize a deal.

You may also be interested in...



FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs

Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.

FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs

Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.

People In The News: Tracking The Latest Industry Personnel Moves

Presidents and CEOs

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel